Trade Summary

3 days ago, Rubin Paul D, serving as Chief Medical Officer at Bioage Labs, Inc. (BIOA), sold 8,820 shares at $17.81 per share, for a total transaction value of $157,084.00.

This sale represents a 100.00% decrease in Rubin Paul D's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Bioage Labs, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.